459 related articles for article (PubMed ID: 8580223)
21. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
[TBL] [Abstract][Full Text] [Related]
22. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
[TBL] [Abstract][Full Text] [Related]
23. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Apud JA; Egan MF; Wyatt RJ
Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
[TBL] [Abstract][Full Text] [Related]
24. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia.
Pourcher E; Cohen H; Cohen D; Baruch P; Bouchard RH
Brain Cogn; 1993 Sep; 23(1):81-7. PubMed ID: 8105825
[TBL] [Abstract][Full Text] [Related]
25. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
[TBL] [Abstract][Full Text] [Related]
26. Clozapine-induced tardive dyskinesia: a case report.
Ertugrul A; Demir B
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):633-5. PubMed ID: 15866369
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced parkinsonism: relationship to age at onset of schizophrenia.
Sandyk R; Kay SR
Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777
[TBL] [Abstract][Full Text] [Related]
28. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
29. Tardive dyskinesia, impaired recall, and informed consent.
Ganguli R; Raghu U
J Clin Psychiatry; 1985 Oct; 46(10):434-5. PubMed ID: 2864333
[TBL] [Abstract][Full Text] [Related]
30. An electroencephalographic study of psychiatric inpatients with antipsychotic-induced tardive dyskinesia.
Koshino Y; Hiramatsu H; Isaki K; Yamaguchi N
Clin Electroencephalogr; 1986 Jan; 17(1):30-5. PubMed ID: 2869843
[TBL] [Abstract][Full Text] [Related]
31. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
Akbostanci MC; Atbaşoğlu EC; Balaban H
Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
[TBL] [Abstract][Full Text] [Related]
32. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
Cassady SL; Thaker GK; Tamminga CA
Psychopharmacol Bull; 1993; 29(2):235-40. PubMed ID: 8290671
[TBL] [Abstract][Full Text] [Related]
34. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.
van Os J; Walsh E; van Horn E; Tattan T; Bale R; Thompson SG
Acta Psychiatr Scand; 2000 Apr; 101(4):300-6. PubMed ID: 10782550
[TBL] [Abstract][Full Text] [Related]
35. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.
Tenback DE; van Harten PN; Slooff CJ; van Os J
J Psychopharmacol; 2010 Jul; 24(7):1031-5. PubMed ID: 19487321
[TBL] [Abstract][Full Text] [Related]
36. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.
Tenback DE; van Harten PN; Slooff CJ; van Os J;
Compr Psychiatry; 2007; 48(5):436-40. PubMed ID: 17707251
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of tardive dystonia in patients with chronic schizophrenia.
Sachdev P
Aust N Z J Psychiatry; 1991 Dec; 25(4):446, 448. PubMed ID: 1686546
[No Abstract] [Full Text] [Related]
38. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
Lee JG; Shin BS; Lee YC; Park SW; Kim YH
Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
[TBL] [Abstract][Full Text] [Related]
39. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
[TBL] [Abstract][Full Text] [Related]
40. [Schizophrenic deficit syndrome and neurologic tolerance].
Verdoux H; Bourgeois M
Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
